| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 09/07/2001 | CA2401151A1 Anti-infective ectatm |
| 09/07/2001 | CA2401022A1 Methods for treating fsh related conditions with gnrh antagonists |
| 09/07/2001 | CA2400657A1 Derivatives of quinoline as alpha-2 antagonists |
| 09/07/2001 | CA2400649A1 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors |
| 09/07/2001 | CA2399704A1 Pyrimidine compounds |
| 09/07/2001 | CA2398685A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents |
| 09/07/2001 | CA2397690A1 Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| 09/07/2001 | CA2397657A1 Farnesyl protein transferase inhibitor combinations with platinum compounds |
| 09/07/2001 | CA2397502A1 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/07/2001 | CA2397448A1 Farnesyl protein transferase inhibitor combinations with further anti-cancer agents |
| 09/07/2001 | CA2397446A1 Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| 09/07/2001 | CA2397425A1 Farnesyl protein transferase inhibitor combinations with taxane compounds |
| 09/07/2001 | CA2397256A1 Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| 09/07/2001 | CA2397253A1 Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| 09/07/2001 | CA2397240A1 Farnesyl protein transferase inhibitor combinations with camptothecin compounds |
| 09/07/2001 | CA2397165A1 Thienopyridine derivatives, their production and use |
| 09/07/2001 | CA2396504A1 Inhibitors of hepatitis c virus ns3 protease |
| 09/07/2001 | CA2339676A1 Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection |
| 09/06/2001 | US20010020191 Differential treatment of prosthetic devices |
| 09/06/2001 | US20010020114 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 09/06/2001 | US20010020095 High affinity for D4 receptors; treatment of schizophrenia, other psychoses, anxiety disorders, depression, alcohol abuse, impulse control disorders, aggression |
| 09/06/2001 | US20010020042 Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 09/06/2001 | US20010020040 Hyperforin derivatives, use thereof and formulations containing them |
| 09/06/2001 | US20010020034 Isothiazole derivatives useful as anticancer agents |
| 09/06/2001 | US20010020025 Mixture of antiserotonine compound with laxative; therapy for constipation |
| 09/06/2001 | US20010020024 Opioid analgesics |
| 09/06/2001 | US20010020022 2{3-[4-(2-t-butyl-6-trifluoromethylpyridin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol-fumarate |
| 09/06/2001 | US20010020021 Metalloprotease inhibitor |
| 09/06/2001 | US20010020013 Polymerase inhibitors |
| 09/06/2001 | US20010020009 Using plant extract |
| 09/06/2001 | US20010020006 Dipeptidyl peptidase; antidiabetic agents |
| 09/06/2001 | US20010020005 Administering a gastrin inhibitor |
| 09/06/2001 | US20010019715 Administering a cytotoxic T-lymphocyte and one agent capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors |
| 09/06/2001 | US20010019714 Hiv-specific cytotoxic t-cell responses |
| 09/06/2001 | DE10008159A1 Verwendung von 2-Methyl-thiazolidin-2,4-dicarbonsäure (2-MTDC) und /oder ihrer physiologisch verträglichen Salze zur Behandlung und/oder Prophylaxe von Krebserkrankungen Use of 2-methyl-thiazolidine-2,4-dicarboxylic acid (2-MTCD) and / or their physiologically tolerable salts for the treatment and / or prophylaxis of cancer |
| 09/06/2001 | DE10006889A1 Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen Use of inhibitors of caspase-3 or caspase-activated deoxyribonuclease (CAD) for the treatment of heart disease |
| 09/05/2001 | EP1130122A2 Methods for the diagnosis of polymorphisms in the human EP1-R gene |
| 09/05/2001 | EP1130098A2 Mammalian osteoregulins |
| 09/05/2001 | EP1130087A2 A method to identify compounds that alter the apoptotic process |
| 09/05/2001 | EP1130017A2 Azole derivatives and their use as superoxide radical inhibitors |
| 09/05/2001 | EP1129721A2 The use of isolated domains of type IV collagen to modify cell and tissue interactions |
| 09/05/2001 | EP1129720A2 Stabilized granulocyte colony stimulating factor |
| 09/05/2001 | EP1129718A2 Therapeutic uses of bactericidal/permeability increasing protein products |
| 09/05/2001 | EP1129707A2 Methods for identifying and treating resistant tumors |
| 09/05/2001 | EP1129706A2 Use of cGMP PDE5 inhibitors for the treatment of neuropathy |
| 09/05/2001 | EP1129205A1 Transfection of male germ cells for generation of selectable transgenic stem cells |
| 09/05/2001 | EP1129204A1 Novel system for regulating transgene expression |
| 09/05/2001 | EP1129199A2 Cell signaling polypeptides and nucleic acids |
| 09/05/2001 | EP1129191A1 Methods of diagnosing or treating neurological diseases |
| 09/05/2001 | EP1129190A1 Human tslp dna and polypeptides |
| 09/05/2001 | EP1129188A1 Pge synthase and methods and means for modulating its activity |
| 09/05/2001 | EP1129181A2 Mammalian subtilisin/kexin isozyme ski-1: a proprotein convertase with a unique cleavage specificity |
| 09/05/2001 | EP1129110A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof |
| 09/05/2001 | EP1129108A1 Caspases and apoptosis |
| 09/05/2001 | EP1129096A2 Crf receptor antagonists and methods relating thereto |
| 09/05/2001 | EP1129093A1 Pyrazolopyrimidinone derivatives for the treatment of impotence |
| 09/05/2001 | EP1129086A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| 09/05/2001 | EP1129084A2 Ppar gamma ligands |
| 09/05/2001 | EP1129078A2 Indazole derivatives with 5-ht2 receptor activity |
| 09/05/2001 | EP1129075A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors |
| 09/05/2001 | EP1129074A2 Antrhranilic acid amides and the use thereof as medicaments |
| 09/05/2001 | EP1129072A2 N-substituted azacycles, their preparation and their use as orl-1 receptor ligands |
| 09/05/2001 | EP1129070A1 Neurotrophic diamide and carbamate agents |
| 09/05/2001 | EP1129068A1 Bicyclic signal transduction inhibitors, composition containing them and uses thereof |
| 09/05/2001 | EP1128842A1 Method of treating heparin-induced thrombocytopenia |
| 09/05/2001 | EP1128833A1 Use of agonists of glucocorticosteroid receptors and/or mineral corticosteroid receptors, especially corticosteroids to treat addictions |
| 09/05/2001 | EP1128825A1 A new composition |
| 09/05/2001 | EP1128823A1 Use of propionyl l-carnitine for the preparation of a medicament capable of inducing apoptosis |
| 09/05/2001 | EP1128727A1 Method for treating a patient with neoplasia by treatment with a paclitaxel derivative |
| 09/05/2001 | EP1059889A4 Treatment of brain edema using carbonic anhydrase enzyme inhibitor |
| 09/05/2001 | EP0944612B1 N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate |
| 09/05/2001 | EP0873304B1 Metalloproteinase inhibitors |
| 09/05/2001 | EP0832061B1 Benzamide derivatives and their use as vasopressin antagonists |
| 09/05/2001 | EP0830345B1 Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation |
| 09/05/2001 | EP0777646B1 Metalloproteinase inhibitors |
| 09/05/2001 | CN1311822A Gene therapy method |
| 09/05/2001 | CN1311797A Process for producing immunolobulins for intravenous administration and other immunolobulin products |
| 09/05/2001 | CN1311789A Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity |
| 09/05/2001 | CN1311785A Tetrahydroquinoline derivatives as glycine antagonists |
| 09/05/2001 | CN1311779A Succinoylamino lactams as inhibitors and as A beta protein production |
| 09/05/2001 | CN1311775A Pyrrole substituted 2-indolinone protein kinase inhibitors |
| 09/05/2001 | CN1311772A New 3-aryl-2-hydoxy-propionic acid derivative I |
| 09/05/2001 | CN1311692A Farnesyl protein transferase inhibitors with i(IN VIVO) Radiosensitizing |
| 09/05/2001 | CN1311690A Porcine circovirus and parvovirus vaccine |
| 09/05/2001 | CN1311688A Synthetic somatostatin immunogen for growth promotion in farm animals |
| 09/05/2001 | CN1311687A Glucagon-like peptide-1 improves beta-cell response to glucose in subjects with impaired glucose tolerance |
| 09/05/2001 | CN1311682A Pharmaceutical compositions and uses for androst-5-ene-3beta, 17 beta-diol |
| 09/05/2001 | CN1311681A combination therepy for treatment of refractory depression |
| 09/05/2001 | CN1311679A Benzimidazole derivatives as modulators of IgE |
| 09/05/2001 | CN1311678A Substituted tricyclic pyrazole derivatives with protein kinase activity |
| 09/05/2001 | CN1311676A Compound that inhibit the binding of integrins to their receptors |
| 09/05/2001 | CN1311675A Compounds having IgE affecting properties |
| 09/05/2001 | CN1311674A Antioxidant, antiproliferous compositions, comprising a carnitine and a cerotenoid |
| 09/05/2001 | CN1311670A Cholinergic agents in the treatment of presbyopia |
| 09/05/2001 | CN1311629A Inhibitors of transcription factor NF-KB |
| 09/05/2001 | CN1311026A Medicine for curing lupus erythematosus brain disease |
| 09/05/2001 | CN1311025A Medicine for curing lupus erythematosus etc. immune diseases induced diseases |
| 09/05/2001 | CN1311015A Natural medicine for anti-virus, anti-heavy metals and anti-tumor |
| 09/05/2001 | CN1070492C Tetracylic derivatives, process for prepn. of same and use |
| 09/05/2001 | CN1070491C Process for preparing 1-butyl-2-[2'-(2H-teazol-5-yl)-biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid |